Department of Health and Human Services January 9, 2008 – Federal Register Recent Federal Regulation Documents
Results 1 - 19 of 19
Determination That INDERAL (Propranolol Hydrochloride) Tablets, 10 Milligrams, 20 Milligrams, and 90 Milligrams Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA) has determined that INDERAL (propranolol hydrochloride (HCl)) Tablets, 10 milligrams (mg), 20 mg, and 90 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to the drug products, and it will allow FDA to approve ANDAs for propranolol HCl tablets, 10 mg, 20 mg, and 90 mg as long as they meet relevant legal and regulatory requirements.
Memorandum of Understanding Between the Food and Drug Administration and Regents of the University of California
The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the University of California, Davis campus (UC Davis). The purpose of this MOU is to establish terms of collaboration between FDA and UC Davis, focused primarily but not exclusively, in the areas of the safety and security of foods and cosmetics, animal feeds and veterinary products. Beyond the collaborations in the traditional academic programs for training, research and outreach, this MOU will also include UC Davis extended partnerships such as the Western Institute for Food Safety and Security, and the Center for Produce Safety.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
